𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Maintenance infliximab therapy in patients with crohn’s disease: how long, how much, how frequent?

✍ Scribed by Carmen Cuffari; Gary R Lichtenstein

Book ID
119426556
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
59 KB
Volume
124
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term outcome of maintenance inflixi
Long-term outcome of maintenance infliximab therapy in children with Crohn's disease
✍ Jeffrey S. Hyams; Trudy Lerer; Anne Griffiths; Marian Pfefferkorn; Subra Kugatha 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

Background: Infliximab therapy has short-term benefits in children with moderate-to-severe Crohn's disease (CD). We assessed the long-term outcome of infliximab maintenance therapy in children with CD. ## Methods: We performed a multicenter cohort study of 729 pediatric patients with CD enrolled i

Mucosal healing predicts long-term outco
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease
✍ Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert V 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 395 KB 👁 2 views

Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated. ## Methods: We studied MH during long-term treatment with IFX in 214 CD patients. A total of 183 patients